文献速递临床试验与 GCP基础与转化研究

血管紧张素转换酶抑制剂用于经导管主动脉瓣植入术后患者:多中心随机开放标签盲终点对照试验研究方案

Angiotensin-converting enzyme inhibitor for post-transcatheter aortic valve implantation patients: study protocol for a multicenter randomized, open-label blinded endpoint control trial.
PubMed 文献 · Trials · 2021-07-18

针对TAVI术后最佳药物治疗缺乏随机对照证据、尤其中国人群数据空白的问题,设计多中心随机开放标签盲终点对照试验,计划纳入200例成功TAVI患者,1:1随机接受标准治疗或标准治疗加福辛普利,随访至24个月,用心脏磁共振评估左心室重构,以探讨ACEI对TAVI术后左心室重构的影响。

要点

  • TAVI术后最佳药物治疗尚无推荐,RASi可否逆转左心室重构缺乏RCT证据。
  • 研究纳入200例成功TAVI患者,1:1随机至标准治疗或加福辛普利。
  • 主要评估手段为基线与24个月心脏磁共振左心室重构指标。

核心结论

  • 该研究旨在填补中国TAVI术后患者RASi治疗证据空白,结果尚待报告。

研究设计与样本

  • 多中心随机开放标签盲终点对照试验,计划从中国七家学术医院招募200例成功TAVI患者,1:1随机分组。

主要发现

  • 原文为研究方案,未报告研究结果。

关键数值与推荐

  • 干预组为标准治疗加福辛普利,对照组为标准治疗。
  • 随访时间为随机后30天、3个月、6个月、12个月和24个月。
  • 基线与24个月随访时行心脏磁共振评估左心室重构。

临床怎么用

  • 研究结果将为TAVI术后是否加用ACEI提供随机对照证据,指导术后药物治疗决策。

局限性

  • 开放标签设计,仅终点评估采用盲法。
  • 样本量200例,随访24个月,结果尚未获得。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: With the expanded utilization of transcatheter aortic valve implantation (TAVI) to younger and lower surgical risk patients with severe aortic stenosis (AS), optimal medical therapy after TAVI procedure has become the main concern. Renin-angiotensin system inhibitors (RASi) are widely utilized in the area of cardiovascular disease including heart failure and myocardial infarction and revealed the ability to reverse left ventricular (LV) remodeling. Interests have, thus, been drawn in investigating whether the prescription of RASi after the TAVI procedure can prevent or reverse cardiac remodeling and improve long-term clinical outcomes. No recommendation regarding the prescription of RASi after TAVI is proposed yet due to the lack of evidence from randomized controlled trials, especially in the Chinese population. We, therefore, designed this randomized controlled trial to explore the effect of adding fosinopril to standard care in patients who underwent a successful TAVI procedure on the LV remodeling. METHODS: A total of 200 post-TAVI patients from seven academic hospitals across China will be recruited and randomized with a ratio of 1:1 to receive standard care or standard care plus fosinopril. Follow-up visits will take place at 30 days, 3 months, 6 months, 12 months, and 24 months from randomization to assess the clinical symptoms, any adverse events, cardiac function, and quality of life. Cardiac magnetic resonance will be performed at baseline and repeated at the 24-month follow-up visit to assess LV remodeling. DISCUSSION: This study will provide evidence regarding medical therapy for AS patients who underwent TAVI and filling the gap in the Chinese population. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2100042266 . Registered on 17 January 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Liao YB, Xia C, Cheng Y, et al. Angiotensin-converting enzyme inhibitor for post-transcatheter aortic valve implantation patients: study protocol for a multicenter randomized, open-label blinded endpoint control trial. Trials. 2021. PMID: 34275476. doi:10.1186/s13063-021-05411-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。